Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

NetraMark Holdings Inc C.MEND


Primary Symbol: C.AIAI Alternate Symbol(s):  AINMF

Healthcare Medical Devices
NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows the Company to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that it can work with smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. The typical molecular data used is RNASeq, microarray, single nucleotide polymorphism (SNP) and methylation.


CSE:AIAI - Post by User

NetraMark Holdings Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(86)
•••
Post by yopmemama021on Feb 28, 2022 4:48pm
137 Views
Post# 34469145

MEND

MEND
wrapping up a solid month for $MEND.c $MNNDF
they partnered up with Cyclica to develop novel drugs for neurodegenerative diseases and had George Achilleos take over as CEO.
they launched their game changing AI technology, Netraplacebo, which will transform clinical trial success rates in the US$94B CNS therapeutics Market. $MEND ’s AI can create accurate hypotheses in less than an hour, about diseases that have taken years for pharmaceutical companies to discover
hoping soon with enough volume to see some price action start to reflect these major advancements
$MEND.c steady @$0.68 ,tight share structure with only 40 M OS

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities